SNSR

355%, respectively), with equivalent tumour growth inhibition and ORR. lymphoma (DoHH-2, SuDHL-4), mantle cell lymphoma (Granta 519) and Burkitt's lymphoma (RAMOS). Activity was also monitored in a systemic model of…